TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00057083

Intervention type: OTHER
Group type: OTHER
Intervention: Telemedicine Care
Study: NCT02616068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Patch
Description: Transdermal patch 100 mg once a day for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loxoprofen sodium
Description: Loxoprofen sodium 60 mg per tablet by mouth, every 8 hours for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for loxoprofen sodium)
Description: Placebo (for loxoprofen sodium 60 mg per tablet) by mouth, every 8 hours for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for transdermal patch)
Description: Placebo (for transdermal patch 100 mg) once a day for 7 days
Study: NCT03101930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: subcutaneous liraglutide daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: oral sitagliptin daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hypocaloric diet
Description: Reduced calorie intake to achieve weight loss.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Subjects in the liraglutide arm will receive a placebo for sitagliptin. Those in the sitagliptin arm will receive a placebo for liraglutide. All subjects will receive a placebo for Exendin 9-39.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Subjects in the liraglutide arm will receive a placebo for sitagliptin. Those in the sitagliptin arm will receive a placebo for liraglutide. All subjects will receive a placebo for Exendin 9-39.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Subjects in the liraglutide arm will receive a placebo for sitagliptin. Those in the sitagliptin arm will receive a placebo for liraglutide. All subjects will receive a placebo for Exendin 9-39.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin (9-39)
Description: All subjects will receive Exendin (9-39) or matching placebo in crossover fashion during study days on the first and third days of the second week after randomization and again on the 5th and 7th days of the 14th week of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin (9-39)
Description: All subjects will receive Exendin (9-39) or matching placebo in crossover fashion during study days on the first and third days of the second week after randomization and again on the 5th and 7th days of the 14th week of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin (9-39)
Description: All subjects will receive Exendin (9-39) or matching placebo in crossover fashion during study days on the first and third days of the second week after randomization and again on the 5th and 7th days of the 14th week of treatment.
Study: NCT00268463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: Oral capecitabine 850 mg/m2 twice daily on days 1-14 every 21 days for 8 cycles: Arm 1~Oral capecitabine 850 mg/m2 twice daily on days 22-35 every 42 days for 4 cycles and then on days 1-14 every 21 days for 4 cycles: Arm 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Oral capecitabine 850 mg/m2 twice daily on days 1-14 every 21 days for 8 cycles: Arm 1~Oral capecitabine 850 mg/m2 twice daily on days 22-35 every 42 days for 4 cycles and then on days 1-14 every 21 days for 4 cycles: Arm 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: floxuridine
Description: Continuous hepatic arterial infusion of floxuridine 0.2 mg/kg on days 1-14 every 42 days for 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: Oxaliplatin 130 mg/m2 IV over 2 hours on day 1 every 21 days for 8 cycles: Arm 1~Oxaliplatin 130 mg/m2 IV over 2 hours on day 22 every 42 days for 4 cycles and then on day 1 every 21 days for 4 cycles: Arm 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Oxaliplatin 130 mg/m2 IV over 2 hours on day 1 every 21 days for 8 cycles: Arm 1~Oxaliplatin 130 mg/m2 IV over 2 hours on day 22 every 42 days for 4 cycles and then on day 1 every 21 days for 4 cycles: Arm 2
Study: NCT02964988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of PET tracer 68Ga-NOTA-AE105
Description: Following injection of 68Ga-NOTA-AE105 the patients will be subjected to whole body PET/CT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Whole body PET/CT
Study: NCT00388167

Intervention type: DRUG
Intervention: Caspofungin
Description: The patients are treated with 70 mg IV of caspofungin on day 1, followed by 50 mg/day IV during the rest of treatment
Study: NCT04823546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: activity based therapy
Description: Standing and reaching (2) Sit-to-stand (3) Stepping forward and backward onto blocks (4) Stepping sideways onto blocks (5) Forward step up onto blocks (6) Raising and lowering of heel (7) Standing with the base of support constrained with feet in parallel and tandem conditions Phase 2 started after 3 weeks. Phase 2 included the phase 1 exercise along with below exercise. (10) Walking on a treadmill; (11) Walking over various surfaces and obstacles;

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength Training
Description: Strength training included for hip • flexor and extensors and abductors, knee extensors, and ankle dorsi flexors and plantar •flexors. Apart from using body weight, sandbag weights and Therabands of eight different resistances
Study: NCT00167362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive enhancement therapy (CET)
Description: Using 80 to 100 hours of graduated exercises in computer assisted training, coupled with structured but unrehearsed in vivo social group interactions, CET tries to shift an early developmental reliance on effortful, serial and verbatim cognitive processing to a more gistful, less effortful and spontaneous abstraction of social themes. CET uses attention, memory and problem solving software from three exercises from Ben-Yishay's Orientation Remediation Module (the Attention Reaction Conditioner, Zero Accuracy Conditioner, and Time Estimates) that are graduated in difficulty and designed to enhance vigilance, selective attention, the ability to shift between auditory and visual modalities, and rapid decision-making.
Study: NCT04642521

Intervention type: DEVICE
Intervention: Jamar hydraulic hand dynamometer
Description: The strength of the dominant hand will be recorded before and after receiving intravenous iron.~Each participant will be positioned in a straight back chair with both hand and feet flat on the ground, elbow flexed to 90 degrees with forearm and wrist in the neutral position. Patient's muscle strength will then be tested three times with an interval of one minute between testing and the average of three times will be recorded to the nearest 0.1kg.

Intervention type: DEVICE
Intervention: Jamar hydraulic hand dynamometer
Description: The strength of the dominant hand will be recorded before and after receiving intravenous iron.~Each participant will be positioned in a straight back chair with both hand and feet flat on the ground, elbow flexed to 90 degrees with forearm and wrist in the neutral position. Patient's muscle strength will then be tested three times with an interval of one minute between testing and the average of three times will be recorded to the nearest 0.1kg.
Study: NCT00167362

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Enriched supportive therapy (EST)
Description: EST is the commonly recommended (Spaulding 1992) treatment for control and experimental subjects in psychosocial trials. EST is a two-staged treatment that requires weekly one-hour sessions in Phase 1 and biweekly sessions in Phase 2. Some practice principles (e.g., psychoeducation and relaxation training) are provided during the group exercises for CET patients, but individually for EST patients. No attempt is made to control for hours of contact between EST and CET, since offering three hours of supportive therapy to EST subjects is neither logistically feasible nor faithful to the goals and methods of supportive therapy. Further, neurobiological hypotheses related to treatment specificity would be best tested by clear differences in treatment intensity and content.
Study: NCT03954379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (ACB, SA, peri-op pain management)
Description: INTERVENTION BEFORE SURGERY~Adductor Canal Block will be done using Adductor canal catheter (tube in the thigh) + injection of freezing medication~INTERVENTION DURING SURGERY~IV propofol for sedation~INTERVENTION AFTER SURGERY~Injection of salty water through the tube in the thigh x 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPACK and multi-modal analgesic regimen
Description: INTERVENTION BEFORE SURGERY~1. Adductor Canal Block will be done using Adductor canal catheter (tube in the thigh) + injection of freezing medication~2. iPACK block ( infiltration between Popliteal Artery and posterior Capsule of the Knee) - injection of freezing medication in the back of the knee~INTERVENTION DURING SURGERY~1. IV dexmedetomidine~2. IV ketamine Both for sedation~INTERVENTION AFTER SURGERY~1. injection of freezing medication through the tube in the thigh x 2~2. IV dexamethasone 8 mg 1 day after surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periarticular Local Anesthetic Infiltration
Description: INTERVENTION DURING SURGERY

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periarticular Local Anesthetic Infiltration
Description: INTERVENTION DURING SURGERY

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Dexamethasone 8mg at the end of surgery as standard of care
Description: INTERVENTION DURING SURGERY

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Dexamethasone 8mg at the end of surgery as standard of care
Description: INTERVENTION DURING SURGERY
Study: NCT03998761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micronized Progesterone
Description: Progesterone will be started when endometrial thickness reached 8 mm or more. Patients will receive micronized progesterone (Cyclogest® 400mg; Actavis) at the dose of 400mg twice daily (morning and evening). A maximum of 2 embryos will be thawed on the day of embryo transfer, which is four days or six days after the start of progesterone depending on day-3 or day-5 embryo transfer. After thawing, surviving embryos will be transferred into the uterus under ultrasound guidance. Estradiol and progesterone will be continued until the day of pregnancy test. If the pregnancy test is positive, the patients will continue to use 800 mg micronized progesterone until 7 weeks of gestation.
Study: NCT00928187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)
Description: Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)
Description: Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight \< 60 kg, 400 mg if weight \> 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
Description: Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food
Study: NCT03650868

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracal paravertebral block
Description: Thoracal paravertebral block will be performed before the surgery to the TPVB group.
Study: NCT02235571

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iChoose Kidney Decision Aid
Description: Providers will use a shared decision making tool with patients via iPhone, iPad, or web which explains predicted individualized risk of mortality on dialysis vs. transplant during the evaluation appointment for kidney transplant.
Study: NCT06220877

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccal Pad of Fat
Description: surgical procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A-PRF
Description: blood sample

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fibrin glue
Description: procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oxidized cellulose
Description: procedure
Study: NCT01738633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutritional counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutritional counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: respirology counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: respirology counseling
Study: NCT03150147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-ischemic preservation
Description: The device is a portable heart-lung machine; an automatic pressure and flow-controlled perfusion system. The heart is submerged in a solution and the medium is circulated in the heart, at a temperature of 8°C.

Intervention type: OTHER
Group type: OTHER
Intervention: Ischemic cold static storage
Description: Standard ischemic cold static storage; a crystalloid solution (cardioplegia) is used to stop and preserve the heart. Cardioplegia is given. The heart is storage i a transport box containing ice to keep the temperature around 8°C.
Study: NCT03855345

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: The treatment will consist of oral hygiene orientation, with instructions of brushing technique and recommendation of the daily use of dental floss. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with ultrasound equipment and curettes for root scaling and straightening. After the use of ultrasound and curettes, bicarbonate jet will be used to remove dental biofilm. Treatment will be performed in 2 to 4 sessions under local anesthesia (typically 2% mepivacaine with 1: 100,000 noradrenaline). Gracey periodontal curettes (numbers 3/4, 7/8, 11/12 and 13/14) and Mc Call curettes for removal of the dental calculus will be used. Other biofilm-retaining factors, such as carious lesions, condemned teeth, and ill-adapted restorations, will be removed during these periodontal treatment sessions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: The treatment will consist of oral hygiene orientation, with instructions of brushing technique and recommendation of the daily use of dental floss. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with ultrasound equipment and curettes for root scaling and straightening. After the use of ultrasound and curettes, bicarbonate jet will be used to remove dental biofilm. Treatment will be performed in 2 to 4 sessions under local anesthesia (typically 2% mepivacaine with 1: 100,000 noradrenaline). Gracey periodontal curettes (numbers 3/4, 7/8, 11/12 and 13/14) and Mc Call curettes for removal of the dental calculus will be used. Other biofilm-retaining factors, such as carious lesions, condemned teeth, and ill-adapted restorations, will be removed during these periodontal treatment sessions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: aPDT
Description: aPDT will be performed at the end of each periodontal treatment session, at sites with bags greater than or equal to 4 mm. The photosensitizer PapaMBlue® (F \& A Ltda, São Paulo, Brazil) will be deposited in the pouches with a syringe, with the application in coronal direction, and a time of 1 min of pre-irradiation will be adopted so that the substance can stain bacterial biofilm (according to the manufacturer's information). Next, the diode laser emitting wavelength of ʎ=660 nm, with power of P=100 mW, will be applied. The laser will be applied to the mucosa, over the oral epithelium with an optical fiber. Irradiation will be performed until the entire periodontal pocket is illuminated for 2 min at each point. Each irradiation point will be approximately 0.4cm2, which will result in energy density of 30 J/cm2 in 2 min irradiation. The irradiation will have a constant power density of 250 mW/cm2.
Study: NCT04530201

Intervention type: DEVICE
Group type: OTHER
Intervention: Colli-Pee Small Volumes (10 mL) device
Description: Women will self-collect two first-void urine samples at home the day prior to colposcopy using the new generation Colli-Pee Small Volumes (10 mL) device (Novosanis, Belgium). The collector tube will be prefilled with a non-toxic nucleic acid preservative including an internal process control.
Study: NCT00604552

Intervention type: DEVICE
Group type: OTHER
Intervention: AneuRx Stent Graft
Description: Abdominal Aortic Aneurysm Repair
Study: NCT03998761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micronized progesterone plus dydrogesterone
Description: Progesterone will be started when endometrial thickness reached 8 mm or more. Patients will receive micronized progesterone (Cyclogest® 400mg; Actavis) at the dose of 400mg twice daily (morning and evening) plus dydrogesterone (Duphaston® 10mg, Abbott) at the dose of 10mg twice daily (morning and evening). A maximum of 2 embryos will be thawed on the day of embryo transfer, which is four days or six days after the start of progesterone depending on day-3 or day-5 embryo transfer. After thawing, surviving embryos will be transferred into the uterus under ultrasound guidance. Estradiol and progesterone will be continued until the day of pregnancy test. If the pregnancy test is positive, the patients will continue to use 800 mg micronized progesterone plus 20 mg dydrogestetrone until 7 weeks of gestation.
Study: NCT05476120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BATHE
Description: The BATHE interview technique was applied 3 times, once every 3 months, for 6 months.
Study: NCT02227147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF 20µg/ml
Study: NCT03423433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heel raise intervention
Description: A daily heel-raise programme for ten weeks to determine any chronic effects of heel raises on the previously mentioned variables.
Study: NCT02227147

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Formulation containing antioxidant
Study: NCT01186601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET tracer (BAY94-9392)
Description: A radioactive dose of 300 MBq of the study drug with a total quantity of \</= 0.1 mg will be administered as slow intravenous bolus injection over up to 60 seconds
Study: NCT02684708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide, vincristine, prednisone, dacarbazine
Description: 28-day chemotherapy cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclo, vcr, pred, dacarb,etop and doxo
Description: 21-day chemotherapy cycle
Study: NCT00915928

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril
Description: 2,5 mg daily for 3 months
Study: NCT01603173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate Tablets 25 mg
Description: 25 mg tablet once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine Fumarate
Description: 25 mg tablet once a day
Study: NCT00915928

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dayli for 3 months
Study: NCT00815048

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine/Remifentanil
Description: Atropine 20mcg/kg~Remifentanil 3mcg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl/Atropine/Succinylcholine
Description: Atropine 20mcg/kg~Fentanyl 2mcg/kg~Succinylcholine 2mg/kg
Study: NCT00003631

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Study: NCT01464034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days
Study: NCT00003631

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01918865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS-PTP1BRx

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daily OAD (metformin and/or sulfonylurea)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: daily OAD (metformin and/or sulfonylurea)
Study: NCT04494828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine hydrochloride (200 μg/2 ml) is diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour (dexmedetomidine 0.1 μg/kg/hour). The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline group
Description: Normal saline is also diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour, which is the same with the dexmedetomidine group. The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
Study: NCT01464034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: PO daily on Days 1-21, every 28 Days
Study: NCT03253523

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Occipital neurolysis
Description: Surgical occipital nerve decompression
Study: NCT00645840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Patients will receive daily anakinra therapy for 28 days
Study: NCT00729443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3241
Description: single oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02452385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082 tablet
Description: CM082 tablets taken orally